天康生物 重要提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会未涉及变更以往股东大会已通过决议的情况。 一、 会议召开和出席情况 （一）会议召开时间 证券代码：002100 证券简称：天康生物 公告编号：2024-038 天康生物股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 现场会议时间：2024 年 5 月 20 日上午 11：00 时 网络投票时间：2024 年 5 月 20 日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为 2024 年 5 月 20 日上午 9:15—9:25，9:30—11:30 和下 午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时间 为 2024 年 5 月 20 日上午 9：15 至下午 15:00 任意时间。 （二）会议召开地点：新疆乌鲁木齐市高新区长春南路 528 号天康企业大 厦 11 楼公司 4 号会议室。 （三）会议召开方式：现场投票与网络投票相结合的方式。 （四）会议召集人：公司董事会 （五）主持人： ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-037 天康生物股份有限公司 关于 2024 年 4 月份生猪销售简报 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、2024 年 4 月份生猪销售情况 天康生物股份有限公司（以下简称"公司"）2024 年 4 月份销售生猪 24.09 万头，销量环比下降 7.06%，同比下降 1.83%；销售收入 3.80 亿元，销售收入环 比下降 12.04%，同比下降 8.87%。 天康生物 | 2024 | 年 | 2 | 月 | 15.60 | 38.81 | 2.44 | 5.83 | 13.27 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2024 | 年 | 3 | 月 | 25.92 | 64.72 | 4.32 | 10.15 | 13.72 | | 2024 | 年 | 4 | 月 | 24.09 | 88.81 | 3.80 | 13.95 | 14.46 | 注：因四舍五入，以上数据可能存在尾差 ...

Investment Rating - Maintain "Buy" rating [16][18] Core Views - The company's pig farming costs improved in Q1 2024, with profits turning positive year-on-year [2] - The company's pig production volume is expected to grow steadily, with a target of 3-3.5 million heads in 2024 [7] - The feed business achieved both volume and profit growth in 2023, with sales reaching 2.804 million tons, up 20.75% YoY [17] - The animal vaccine business saw rapid growth in 2023, with sales reaching 1.74 billion doses, up 33.15% YoY [21] - The industry's losses are driving a new round of capacity reduction, and pig prices are expected to enter an upward cycle in 2024 [12] Financial Performance - In Q1 2024, the company achieved revenue of 3.78 billion yuan, down 2.9% YoY, but net profit turned positive to 54.06 million yuan [6] - The company's revenue in 2023 was 19.03 billion yuan, up 12.0% YoY, but net profit turned negative to -1.36 billion yuan [10] - The company's gross margin improved from 2.9% in 2023 to 12.1% in 2024E, and is expected to reach 14.5% by 2026E [3] - The company's ROE improved from -21.3% in 2023 to 8.5% in 2024E, and is expected to reach 13.3% by 2026E [3] - The company's EPS is expected to be 0.43, 0.72, and 0.89 yuan in 2024-2026, with corresponding P/E ratios of 17.7x, 10.7x, and 8.6x [18] Industry Outlook - Pig prices in Q1 2024 averaged 14.4 yuan/kg, down 4% YoY, but piglet prices rose significantly after the Spring Festival due to increased demand [2] - The industry's sow inventory at the end of Q1 2024 was 39.92 million heads, down 7.3% YoY, indicating a reduction in capacity [12] - Pig prices are expected to rise in the second half of 2024 due to reduced supply and increased seasonal demand [12] Business Segments - The company's pig production in 2023 reached 2.816 million heads, up 39% YoY, with fattening pigs accounting for 2.595 million heads [10] - The company's feed business revenue in 2023 was 6.49 billion yuan, up 17.4% YoY, with a gross margin of 10.2% [17] - The company's animal vaccine business revenue in 2023 was 1.0 billion yuan, up 5.9% YoY, with a gross margin of 62.6% [21]

口口 天康生物20240430_智能速览 2024年05月03日 07:51 关键词 净利润 营业收入 负债率 饲料业务 制药业务 养殖业务 玉米收储业务 减值准备 产能利用率 能繁母猪 饲 料成本 动保业务 151万头 14.9块 1.5亿 63% 315万吨 母猪 24年 内销 全文摘要 公司2023年的营业总收入达到了190.26亿元，同比增长11.99%，但是净利润却出现了显著下降，录 得-13.63亿元，同比下滑了585.55%。这一现象的主要原因是包括养殖在内的多个业务板块虽有不同程 度的增长，但在养殖业务上因为计提了4.54亿元的减值准备而导致整体收益呈现亏损状态。具体而 言，饲料业务增长了17.37%，全年销量增长了20.75%；制药业务增长了5.93%，养殖业务的出栏量则增长 了38.9%；植物蛋白及优质加工业务增长了24.15%，而玉米收储业务也实现了1.56%的增长。在面对养殖 业的种种挑战和困境时，公司采取了多维度的战略调整和优化，包括但不限于成本控制、业务结构调整 以及市场拓展等措施，旨在增强公司的抗风险能力和市场竞争力。此外，公司还展开了对外部环境的敏 锐洞察，诸如对猪瘟疫情的影响 ...

| --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

公 司 研 究 生猪成本下降出栏稳增，饲料业务持续成长 生猪成本下降出栏稳增，饲料业务持续成长，维持"买入"评级 2023 年公司生猪养殖营收 55.41 亿元(+8.05%)，全年生猪出栏 281.58 万头 (+38.90%)，销售均价 14.2 元/公斤，2023Q4 完全成本受非瘟影响上升至 17.6 元/ 公斤。2024Q1 公司实现生猪出栏 64.72 万头(+13.66%)，完全养殖成本下降至 16 元/公斤（2024 年 3 月降至 15.3 元/公斤左右），预计 2024H2 完全成本降至 15.5 元/公斤。生产指标方面，2024Q1 公司 PSY 达 24.12，窝均活仔数 12 头，7kg 断 奶仔猪成本 345 元/头，截至 2024 年 3 月末，公司能繁存栏约 14 万头，预计 2024 年公司生猪出栏 300-350 万头，2026-2027 年实现 500 万头生猪出栏目标。公司 生猪养殖持续推进降本增效，生猪出栏稳步提高，猪周期反转受益。 股价走势图 开 源 证 券 证 券 研 究 报 告 公司信息更新报告 相关研究报告 公司信息更新报告 | --- | --- | --- ...

Investment Rating - The report maintains a "Recommended" rating for the company [11][18]. Core Insights - The company achieved a revenue of 19.03 billion yuan in 2023, a year-on-year increase of 12.0%, but reported a net loss attributable to shareholders of 1.36 billion yuan, a significant decline of 585.5% year-on-year [10][21]. - In Q1 2024, the company generated a revenue of 3.78 billion yuan, a decrease of 2.9% year-on-year, but successfully turned a profit with a net income of 50 million yuan [10][11]. - The company aims to sell approximately 300-350 million pigs in 2024, with a target PSY (Pigs per Sow per Year) of around 28 and a complete cost control target of 15.5 yuan/kg [2][11]. Summary by Sections Sales and Production - In 2023, the company sold 2.816 million pigs, an increase of 38.9% year-on-year, with an average selling price of 14.2 yuan/kg, down 18.0% year-on-year [2]. - In Q1 2024, the company sold 647,000 pigs at an average price of 13.4 yuan/kg [2]. Financial Performance - The company reported a net profit of -1.36 billion yuan in 2023, with a significant asset impairment loss of 500 million yuan impacting overall performance [10][21]. - The forecast for net profit attributable to shareholders for 2024-2026 is 518 million, 1.084 billion, and 1.497 billion yuan, respectively, with corresponding EPS of 0.38, 0.79, and 1.10 yuan [11][21]. Business Segments - The feed business achieved a revenue of 6.49 billion yuan in 2023, a year-on-year increase of 17.4%, while the veterinary medicine segment generated 1 billion yuan, up 5.93% [18]. - In Q1 2024, the feed business sold 669,000 tons, a year-on-year increase of 13.5%, and the animal vaccine segment reported a revenue of 340 million yuan, up 13.1% [18]. Cost Management - The company has successfully reduced its pig farming costs, with the complete cost dropping below 16.5 yuan/kg in September and October 2023, and further down to 15.99 yuan/kg in Q1 2024 [2].

Financial Performance - The company's operating revenue for Q1 2024 was ¥3,776,851,559.41, a decrease of 2.93% compared to ¥3,890,843,979.48 in the same period last year[10] - Net profit attributable to shareholders was ¥54,063,760.85, a significant increase of 478.54% from a loss of ¥14,282,251.76 in the previous year[10] - The net profit after deducting non-recurring gains and losses was ¥56,677,250.28, up 514.12% from a loss of ¥13,686,317.97 in the same period last year[10] - The company reported a total comprehensive income of ¥7,566,038.59, compared to -¥7,300,826.24 in the previous period[46] - Basic and diluted earnings per share for the current period are both ¥0.04, compared to -¥0.01 in the previous period[46] - Net profit for the quarter reached ¥60.18 million, a significant recovery from a net loss of ¥17.15 million in the same period last year[52] Cash Flow and Liquidity - The company's cash flow from operating activities showed an improvement, with a net outflow of ¥333,850,669.38, a 36.26% reduction from ¥523,750,573.77 in the previous year[10] - The total cash inflow from operating activities for the current period was approximately ¥3.54 billion, a decrease from ¥3.59 billion in the previous period, reflecting a decline of about 1.1%[33] - The cash received from sales of goods and services was approximately ¥3.53 billion, down from ¥3.57 billion in the previous period, indicating a decrease of about 1.2%[33] - The company's cash and cash equivalents at the end of the period amounted to approximately ¥2.68 billion, a decrease from ¥2.82 billion at the beginning of the period, representing a decline of about 4.9%[40] - The net cash flow from operating activities is -¥333,850,669.38, an improvement from -¥523,750,573.77 in the previous period[47] - Cash and cash equivalents at the end of the period amount to ¥2,548,274,731.17, down from ¥3,802,570,554.95 at the beginning of the period[47] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥17,166,609,324.11, representing a 2.48% increase from ¥16,751,659,614.41 at the end of the previous year[11] - Total liabilities amount to ¥9,227,027,848.72, up from ¥8,836,902,688.33, representing an increase of about 4.4%[46] - Long-term borrowings increased to ¥1,560,100,974.71 from ¥1,225,360,197.17, indicating a growth of approximately 27.3%[46] - The total liabilities decreased to approximately ¥12.66 billion from ¥12.93 billion, indicating a decline of about 2.1%[51] - The company's total equity is reported at ¥7,939,581,475.39, compared to ¥7,914,756,926.08 in the previous period, showing a slight increase[46] - The total equity attributable to shareholders increased to approximately ¥4.5 billion, reflecting a positive trend in shareholder value[52] Shareholder Information - The company had a total of 57,682 common shareholders at the end of the reporting period[19] - The total number of shareholders holding more than 5% of shares was reported, with the largest shareholder holding approximately 294.58 million shares, representing about 21.59% of total shares[30] - The top ten shareholders collectively held approximately 1.32 billion shares, accounting for about 98.56% of the total share capital[30] Research and Development - Research and development expenses increased by 65.51% to ¥66,463,953.07, reflecting higher investment in R&D compared to ¥40,156,984.48 in the same period last year[19] - Research and development expenses increased to ¥66.46 million, up from ¥40.16 million, representing a growth of approximately 65%[52] Other Income and Expenses - The company reported a significant increase in other income, which amounted to ¥10,963,408.01, up 31.37% from ¥8,345,527.01 in the previous year[19] - The company reported a decrease in financial expenses to ¥41.54 million from ¥53.76 million, a reduction of about 22.6%[52] Strategic Initiatives - The company has not disclosed any new product developments or market expansion strategies in the current report[28] - The company plans to expand its market presence and invest in new product development to drive future growth[54] - The company is focusing on enhancing its data resources and technology capabilities as part of its strategic initiatives[54] Accounts Receivable and Prepayments - Accounts receivable rose by 62.81% to ¥685,629,062.17, primarily due to increased sales on credit in the pharmaceutical and feed businesses[19] - The accounts receivable increased to approximately ¥685.63 million from ¥421.13 million, showing a significant increase of about 62.8%[40] - The prepayments increased to approximately ¥484.52 million from ¥386.57 million, reflecting an increase of about 25.3%[40]

| --- | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-031 天康生物股份有限公司 第八届监事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"）第八届监事会第八次会议通知 于 2024 年 4 月 16 日以书面专人送达和电子邮件方式发出，并于 2024 年 4 月 25 日（星期四）下午 17：00 在公司 11 楼 4 号会议室召开，公司 3 名监事均参加了 会议。董事会秘书列席了会议，符合《公司法》的有关规定，会议合法有效。会 议由监事会主席张涛女士主持，会议就以下事项形成决议： 一、议案审议情况 （一）审议并通过公司《2023 年年度报告全文及摘要》的议案；（议案内 容详见刊登于 2024 年 4 月 29 日本公司规定信息披露报纸《证券时报》上的《天 康生物股份有限公司 2023 年年度报告摘要》<公告编号：2024-022>和在巨潮资 讯网 www.cninfo.com.cn 上披露的《天康生物股份有限公司 2023 年年度报告全 文》） 同意该项议案的票数为 3 票；反 ...